N/A N=10 Combination Gel and Vascular ND in Mild to Moderate Rosacea
Rosacea
Primary: IGA of Improvement — 3.1; 3.5 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=36 Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
Leukemia, Mast-Cell · Mantle-cell Lymphoma
Primary: Chronic Graft-vs-Host Disease (cGvHD) — 20 percentage of participants
Phase 2 N=55 Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
Prostate Cancer
Primary: Effects of Selenium and Finasteride and Their Combination on PSA Level — 1.9; 1.9; 2.0; 2.1 ng/mL — p=0.5137
Phase 2 N=12 Subcutaneous Immunotherapy for Mouse in Adults
Asthma · Perennial Allergic Rhinitis
Primary: Number of Reported Adverse Events (AEs) — 9; 1; 1; 2 Events
Phase 4 N=115 Polidocanol Versus Glucose Treatment of Telangiectasia Trial
Varicose Veins · Telangiectasis
Primary: Change From Baseline in Extent of Telangiectasias — 57.24; 76.08 percent of change negative values
Phase 1 N=24 Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects
Hepatic Impairment
Primary: Assessment of Maximum Observed Plasma Drug Concentration (Cmax) for Telotristat Ethyl and Comparison Between Each HI Group and Healthy Control Group — 4.06; 6.88; 9.99…
Phase 2 N=33 Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma
Primary: Overall Response Rate — 0; 3; 25; 4 Participants
N/A N=1,479 Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48 — 2.9; 1.6; 2.7; 3.1 Score on a scale — p=0.049
Phase 3 N=113 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors
Hemophilia A
Primary: Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis — 2.9; 23.3 treated bleeds per year — p=<0.0001
Phase 4 N=70 Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart
Hypertension · Left Ventricular Diastolic Dysfunction
Primary: Improvement in Exercise Tolerance — 9; 8 Participants
N/A N=166 Clinical Assessment of DAILIES TOTAL1® (DT1) Multifocal
Refractive Error
Primary: Binocular High Contrast/High Illumination (HC/HI) Visual Acuity (VA) at Intermediate Distance (80 cm) — -0.07; -0.09 logMAR
Phase 2 N=213 LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease
Dry Eye
Primary: Mean Change From Baseline in Global Ocular Discomfort Score at Day 71 — -7.9; -3.6 units on a scale
Phase 2 N=29 A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection
Chronic Hepatitis C Infection
Primary: Percentage of Part 1 Participants With Sustained Virologic Response 12 (SVR12) Weeks Posttreatment — 95.5 percentage of participants
Phase 2 N=37 Iressa Study in Patients With Salivary Gland Cancer
Salivary Gland Cancer
Primary: Response Rate of ZD1839 in Patients With Advanced or Recurrent Salivary Gland Cancer Who Are Not Candidate for Curative Surgery or Radiotherapy — 0; 0; 18; 13 Participants
Phase 2 N=49 A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Objective Response as Per Investigator Assessment According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v. 1.1)…